VTVT

vTv Therapeutics Inc.

Price Chart

Latest Quote

$32.77

+1.03 (+3.23%)

Current Price

Previous Close	$31.74
Open	$31.65
Day High	$32.97
Day Low	$31.50
Volume	60,626

Fetched: 2026-06-13T08:54:20

Stock Information

Shares Outstanding	3.94M
Cash Equivalents	$98.09M
Revenue	$36.84M
Net Income	$2.25M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$129.05M
EPS (TTM)	$-0.78
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$308.50M
Sales	$36.84M
Income	$2.25M
Book/sh	$5.19
Cash/sh	$24.90
Employees	26

Financial Ratios

Quick Ratio	14.26
Current Ratio	14.36

Returns & Margins

ROA	-2.91%
ROE	-1.47%
Gross Margin	34.83%
Operating Margin	63.15%
Profit Margin	6.11%

Ownership

Insider Ownership	38.98%
Institutional Ownership	38.35%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-8.42
P/S	3.50
P/B	6.31

Analyst Data

Recommendation	none
Target Price	$53.00

Technical Indicators

SMA20	$33.66
SMA50	$34.48
SMA200	$31.18
RSI	43.23
ATR	1.8812

Shares Float	2.14M
Short Float	6.60%
Short Ratio	3.72
Volatility	0.27
Rel Volume	1.57

Performance History

Week	+1.94%
Month	+3.47%
Quarter	-1.55%
6 Months	-4.78%
YTD	-17.26%
Year	+98.10%
3 Years	+0.38%
5 Years	-67.75%
10 Years	-86.30%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-12	$32.76	60,700
2026-06-11	$31.59	31,000
2026-06-10	$30.44	17,400
2026-06-09	$31.77	12,700
2026-06-08	$32.06	15,500
2026-06-05	$32.14	40,000
2026-06-04	$34.35	35,600
2026-06-03	$32.94	23,500
2026-06-02	$33.00	24,100
2026-06-01	$34.30	59,600
2026-05-29	$33.35	21,400
2026-05-28	$33.50	28,900
2026-05-27	$33.72	46,100
2026-05-26	$33.16	58,200
2026-05-22	$34.40	60,600
2026-05-21	$35.50	25,100
2026-05-20	$36.60	54,700
2026-05-19	$36.49	65,400
2026-05-18	$35.49	45,100
2026-05-15	$35.69	46,200
2026-05-14	$38.43	147,600
2026-05-13	$31.67	43,000

About vTv Therapeutics Inc.

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.

📰 Latest News

vTv Therapeutics Inc. (NASDAQ:VTVT) Just Beat Earnings: Here's What Analysts Think Will Happen Next

Simply Wall St. • 2026-05-17T13:26:02Z

vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable

Zacks • 2026-05-15T12:55:03Z

Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?

Zacks • 2026-04-20T13:55:02Z

Wall Street Analysts Think vTv Therapeutics (VTVT) Could Surge 31.58%: Read This Before Placing a Bet

Zacks • 2026-04-02T13:55:02Z

vTv Therapeutics (VTVT) Reports $27M 2025 Net Loss Amid Cadisegliatin Advancements

Insider Monkey • 2026-03-18T00:05:18Z

Wall Street Analysts Believe vTv Therapeutics (VTVT) Could Rally 39.86%: Here's is How to Trade

Zacks • 2026-03-17T13:55:02Z

VTv Therapeutics: Q4 Earnings Snapshot

Associated Press Finance • 2026-03-10T20:17:14Z

vTv Therapeutics (VTVT) Secures Global Partnership for PDE4 Inhibitor HPP737

Insider Monkey • 2026-03-04T05:11:48Z

An Alzheimer’s Drug Could Supercharge This High-Risk Stock. Is It Worth a Buy Here?

Barchart • 2026-01-05T16:40:03Z

vTv Therapeutics (VTVT) Upgraded to Buy: Here's What You Should Know

Zacks • 2025-12-24T17:00:05Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$1,017,000	$0	$2,018,000
Operating Revenue	$0	$1,017,000	$0	$2,018,000
Expenses
Interest Expense	$6,000	$0	$13,000	$15,000
Total Expenses	$32,808,000	$25,197,000	$25,502,000	$24,558,000
Other Income Expense	$-136,000	$10,000	$-923,000	$-2,670,000
Other Non Operating Income Expenses	$-136,000	$10,000	$-923,000	$-2,670,000
Net Non Operating Interest Income Expense	$1,864,000	$1,565,000	$459,000	$337,000
Interest Expense Non Operating	$6,000	$0	$13,000	$15,000
Operating Expense	$32,808,000	$25,197,000	$25,502,000	$24,558,000
General And Administrative Expense	$14,947,000	$13,651,000	$11,907,000	$12,201,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-26,974,000	$-18,462,000	$-20,250,000	$-19,164,000
Net Interest Income	$1,864,000	$1,565,000	$459,000	$337,000
Interest Income	$1,870,000	$1,565,000	$472,000	$352,000
Normalized Income	$-26,974,000	$-18,462,000	$-20,250,000	$-19,164,000
Net Income From Continuing And Discontinued Operation	$-26,974,000	$-18,462,000	$-20,250,000	$-19,164,000
Total Operating Income As Reported	$-32,808,000	$-24,180,000	$-25,502,000	$-22,540,000
Net Income Common Stockholders	$-26,974,000	$-18,462,000	$-20,250,000	$-19,164,000
Net Income	$-26,974,000	$-18,462,000	$-20,250,000	$-19,164,000
Net Income Including Noncontrolling Interests	$-31,080,000	$-22,705,000	$-25,966,000	$-25,073,000
Net Income Continuous Operations	$-31,080,000	$-22,705,000	$-25,966,000	$-25,073,000
Pretax Income	$-31,080,000	$-22,605,000	$-25,966,000	$-24,873,000
Interest Income Non Operating	$1,870,000	$1,565,000	$472,000	$352,000
Operating Income	$-32,808,000	$-24,180,000	$-25,502,000	$-22,540,000
Per Share
Diluted EPS	$-3.20	$-3.20	$-9.71	$-10.40
Basic EPS	$-3.20	$-3.20	$-9.71	$-10.40
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-31,058,000	$-22,516,000	$-25,863,000	$-24,766,000
Reconciled Depreciation	$16,000	$89,000	$90,000	$92,000
EBITDA (Bullshit earnings)	$-31,058,000	$-22,516,000	$-25,863,000	$-24,766,000
EBIT	$-31,074,000	$-22,605,000	$-25,953,000	$-24,858,000
Diluted Average Shares	$8,423,632	$5,771,052	$2,084,973	$1,871,905
Basic Average Shares	$8,423,632	$5,771,052	$2,084,973	$1,871,905
Diluted NI Availto Com Stockholders	$-26,974,000	$-18,462,000	$-20,250,000	$-19,164,000
Minority Interests	$4,106,000	$4,243,000	$5,716,000	$5,909,000
Tax Provision	$0	$100,000	$0	$200,000
Research And Development	$17,861,000	$11,546,000	$13,595,000	$12,357,000
Selling General And Administration	$14,947,000	$13,651,000	$11,907,000	$12,201,000
Other Gand A	$14,947,000	$13,651,000	$11,907,000	$12,201,000

Fetched: 2026-06-08

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$64,437,000	$12,199,000	$-24,680,000	$-10,740,000
Total Assets	$89,899,000	$38,266,000	$11,018,000	$33,238,000
Total Non Current Assets	$6,000	$153,000	$361,000	$6,144,000
Other Non Current Assets	$6,000	$153,000	-	-
Current Assets	$89,893,000	$38,113,000	$10,657,000	$27,094,000
Other Current Assets	$218,000	$175,000	-	-
Prepaid Assets	$743,000	$1,192,000	$1,109,000	$2,552,000
Cash Cash Equivalents And Short Term Investments	$88,932,000	$36,746,000	$9,446,000	$12,126,000
Cash And Cash Equivalents	$88,932,000	$36,746,000	$9,446,000	$12,126,000
Receivables	-	$62,000	$102,000	$12,416,000
Accounts Receivable	-	$62,000	$102,000	$173,000
Notes Receivable	-	-	$0	$12,243,000
Current Deferred Assets	-	-	-	$0
Debt
Total Debt	$0	$169,000	$529,000	$716,000
Long Term Debt And Capital Lease Obligation	-	$0	$169,000	$338,000
Current Debt And Capital Lease Obligation	-	$169,000	$360,000	$378,000
Current Debt	-	-	$191,000	$224,000
Other Current Borrowings	-	-	$191,000	$224,000
Liabilities
Total Liabilities Net Minority Interest	$25,462,000	$23,965,000	$29,567,000	$27,399,000
Total Non Current Liabilities Net Minority Interest	$18,821,000	$18,769,000	$18,948,000	$19,691,000
Derivative Product Liabilities	$152,000	$100,000	$110,000	$684,000
Non Current Deferred Liabilities	$18,669,000	$18,669,000	$18,669,000	$18,669,000
Current Liabilities	$6,641,000	$5,196,000	$10,619,000	$7,708,000
Other Current Liabilities	$84,000	-	-	-
Payables And Accrued Expenses	$4,476,000	$3,518,000	$8,776,000	$6,525,000
Payables	$1,132,000	$939,000	$4,075,000	$2,461,000
Accounts Payable	$1,132,000	$939,000	$4,075,000	$2,461,000
Current Deferred Liabilities	-	$0	$17,000	$17,000
Equity
Common Stock Equity	$64,437,000	$12,199,000	$-24,680,000	$-10,740,000
Total Equity Gross Minority Interest	$64,437,000	$14,301,000	$-18,549,000	$5,839,000
Stockholders Equity	$64,437,000	$12,199,000	$-24,680,000	$-10,740,000
Retained Earnings	$-326,692,000	$-299,718,000	$-281,042,000	$-265,524,000
Long Term Equity Investment	-	-	$0	$5,588,000
Preferred Securities Outside Stock Equity	-	-	-	$16,579,000
Other
Ordinary Shares Number	$3,938,654	$2,612,257	$2,084,973	$2,037,090
Share Issued	$3,938,654	$2,612,257	$2,084,973	$2,037,090
Tangible Book Value	$64,437,000	$12,199,000	$-24,680,000	$-10,740,000
Invested Capital	$64,437,000	$12,199,000	$-24,489,000	$-10,516,000
Working Capital	$83,252,000	$32,917,000	$38,000	$19,386,000
Capital Lease Obligations	$0	$169,000	$338,000	$492,000
Total Capitalization	$64,437,000	$12,199,000	$-24,680,000	$-10,740,000
Minority Interest	$0	$2,102,000	$6,131,000	$16,579,000
Additional Paid In Capital	$391,090,000	$311,885,000	$256,335,000	$254,757,000
Capital Stock	$39,000	$32,000	$27,000	$27,000
Common Stock	$39,000	$32,000	$27,000	$27,000
Non Current Deferred Revenue	$18,669,000	$18,669,000	$18,669,000	$18,669,000
Current Capital Lease Obligation	$0	$169,000	$169,000	$154,000
Pensionand Other Post Retirement Benefit Plans Current	$2,081,000	$1,509,000	$1,466,000	$788,000
Current Accrued Expenses	$3,344,000	$2,579,000	$4,701,000	$4,064,000
Long Term Capital Lease Obligation	-	$0	$169,000	$338,000
Current Deferred Revenue	-	$0	$17,000	$17,000
Net PPE	-	$153,000	$361,000	$556,000
Accumulated Depreciation	-	$-508,000	$-487,000	$-397,000
Gross PPE	-	$661,000	$848,000	$953,000
Leases	-	$406,000	$406,000	$406,000
Other Properties	-	$125,000	$244,000	$349,000
Machinery Furniture Equipment	-	$130,000	$198,000	$198,000
Properties	-	$0	$0	$0
Investments And Advances	-	-	$0	$5,588,000
Buildings And Improvements	-	-	$244,000	$349,000

Fetched: 2026-06-08

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-25,255,000	$-25,307,000	$-19,081,000	$-16,043,000
Operating Activities
Operating Cash Flow	$-25,255,000	$-25,307,000	$-19,081,000	$-16,022,000
Cash Flow From Continuing Operating Activities	$-25,255,000	$-25,307,000	$-19,081,000	$-16,022,000
Operating Gains Losses	$142,000	$-10,000	$-3,635,000	$-946,000
Investing Activities
Investing Cash Flow	$0	$0	$4,404,000	$-21,000
Cash Flow From Continuing Investing Activities	$0	$0	$4,404,000	$-21,000
Capital Expenditure	-	-	-	$-21,000
Financing Activities
Issuance Of Capital Stock	$77,476,000	$52,798,000	$12,030,000	$14,786,000
Financing Cash Flow	$77,441,000	$52,607,000	$11,997,000	$14,754,000
Cash Flow From Continuing Financing Activities	$77,441,000	$52,607,000	$11,997,000	$14,754,000
Net Other Financing Charges	$-51,000	-	-	-
Net Common Stock Issuance	$77,476,000	$52,798,000	$12,030,000	$14,786,000
Common Stock Issuance	$77,476,000	$52,798,000	$12,030,000	$14,786,000
Other
Repayment Of Debt	$-392,000	$-191,000	$-599,000	$-808,000
Issuance Of Debt	$392,000	$0	$566,000	$776,000
Interest Paid Supplemental Data	$6,000	$2,000	$14,000	$15,000
Income Tax Paid Supplemental Data	$0	$100,000	$0	$200,000
End Cash Position	$88,932,000	$36,746,000	$9,446,000	$12,126,000
Beginning Cash Position	$36,746,000	$9,446,000	$12,126,000	$13,415,000
Changes In Cash	$52,186,000	$27,300,000	$-2,680,000	$-1,289,000
Proceeds From Stock Option Exercised	$16,000	$0	$0	$9,746,000
Net Issuance Payments Of Debt	$0	$-191,000	$-33,000	$-32,000
Net Short Term Debt Issuance	$-392,000	$-191,000	$-599,000	$-808,000
Short Term Debt Payments	$-392,000	$-191,000	$-599,000	$-808,000
Net Long Term Debt Issuance	$392,000	$0	$566,000	$776,000
Long Term Debt Issuance	$392,000	$0	$566,000	$776,000
Net Business Purchase And Sale	$0	$0	$4,404,000	$0
Sale Of Business	$0	$0	$4,404,000	$0
Change In Working Capital	$1,892,000	$-5,438,000	$4,394,000	$5,385,000
Change In Other Current Liabilities	$-169,000	$-169,000	$-154,000	$0
Change In Other Current Assets	$82,000	$179,000	$68,000	$0
Change In Payables And Accrued Expense	$1,530,000	$-5,215,000	$2,929,000	$-856,000
Change In Prepaid Assets	$449,000	$-216,000	$1,551,000	$-403,000
Stock Based Compensation	$3,775,000	$2,757,000	$1,578,000	$1,272,000
Asset Impairment Charge	$0	$0	$4,245,000	$0
Depreciation Amortization Depletion	$16,000	$89,000	$90,000	$92,000
Depreciation And Amortization	$16,000	$89,000	$90,000	$92,000
Depreciation	$16,000	$89,000	$90,000	$92,000
Gain Loss On Investment Securities	$136,000	$-10,000	$-574,000	$-946,000
Gain Loss On Sale Of PPE	$6,000	$0	$0	-
Gain Loss On Sale Of Business	$0	$0	$-3,061,000	$0
Net Income From Continuing Operations	$-31,080,000	$-22,705,000	$-25,966,000	$-25,073,000
Net PPE Purchase And Sale	-	$0	$0	$-21,000
Purchase Of PPE	-	$0	$0	$-21,000
Change In Other Working Capital	-	$-17,000	-	$6,760,000
Change In Receivables	-	$40,000	$71,000	$-116,000
Changes In Account Receivables	-	$40,000	$71,000	$-116,000
Unrealized Gain Loss On Investment Securities	-	$0	$0	$3,585,000
Long Term Debt Payments	-	-	$-599,000	$-808,000
Other Non Cash Items	-	-	$213,000	$-337,000
Change In Accrued Expense	-	-	-	$0
Change In Interest Payable	-	-	-	$0
Change In Payable	-	-	-	$-856,000
Change In Account Payable	-	-	-	$-856,000

Fetched: 2026-06-08